lifestyle.fairytaleinkbooks.com

Author: FibroBiologics, Inc.

FibroBiologics CEO Issues Letter to Shareholders

May 5, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

May 4, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

April 30, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

April 30, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements

April 20, 2026
FibroBiologics Announces Closing of $3 Million Public Offering

April 2, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering

March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 25, 2026